



TCT Breakfast Session

September 16, 2014

www.sunshineheart.com

Forward Looking Statement



- This presentation contains forward-looking statements. All forward-looking statements are management's present expectations of future events and are subject to a number of risks and uncertainties. Various factors could cause actual results to differ materially from these statements including timing, clinical enrollment, clinical results, financing availability, product sales and marketing or efficacy of products, and the other risks set forth under the caption "Risk Factors" and elsewhere in our periodic and other reports filed with the U.S. Securities and Exchange Commission, including our Annual Report or Form 10-K for the fiscal year ended December 31, 2013.
- Although the Company believes that the forward-looking statements are reasonable and based on information currently available, it can give no assurances that the Company's expectations are correct. All forward looking statements are expressly qualified in their entirety by this cautionary statement.
- Caution: C-Pulse[®] is an investigational device. The device is limited by federal (United States) law to investigational use only.
- C-Pulse is a registered trademark of Sunshine Heart Inc.

Agenda



- Welcome
- Company Updates and Introductions
- OPTIONS HF Post Market Multicenter Trial: Early Experience in Europe: a case study Harefield Hospital UK
- Progress of Fully Implantable Pump
- Single Center Experience with Patient Weaning from the US Feasibility Trial and thoughts from a leading enroller in the COUNTER HF™ US Pivotal Study Can C-Pulse Use Lead To Left Ventricular Recovery?
- Q&A

Jeff Mathiesen

Dave Rosa

Christopher Bowles, PhD

Dr. William E. Cohn

Dr. Sanjeev Aggarwal



Introductions

Dave Rosa